Viking Therapeutics stock surges 18% premarket on positive trial of hip fracture treatment

Shares of Viking Therapeutics Inc. surged 18% in premarket trade Tuesday, after the company announced positive results from a mid-stage trial of a treatment for hip fractures. The biotech, which is working to develop toherapies for metabolic and endocrine disorders, said the Phase 2 trial of its VK5211 program for muscle and bone disorders met its primary goal. “The study achieved statistical significance at all doses with a clear dose-response and, in our view, provides compelling evidence of VK5211’s potent pharmacologic effect on muscle growth,” Viking Chief Executive Brian Lian, Ph.D., said in a statement. Viking shares have gained 154% in 2017, while the S&P 500 has gained 16%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Leave a Reply